[*]
Members listed at end of report.
Dr Kim is currently affiliated with Zafgen, Inc., Cambridge, Massachusetts, USA
Dr Dunayevich is currently affiliated with Amgen, Inc., Thousand Oaks, California,
USA
Disclosure: C.M.A has participated on advisory boards for Allergan, Amylin, Orexigen, Merck,
Johnson and Johnson, Abbott, Arena, Zafgen, Novo Nordisk, and Sanofi-Aventis, and
has received research funding from Lilly, Amylin, Pfizer, Sanofi-Aventis, Orexigen,
MetaProteomics, and the Dr. Robert C. and Veronica Atkins Foundation. L.J.A. has participated
in advisory boards/acted as a consultant for Amylin Pharmaceuticals, Inc., Ethicon
Endo-Surgery, Inc., GlaxoSmithKline Consumer Healthcare LP, Novo Nordisk, Orexigen
Therapeutics, Inc., VIVUS, Inc., Takeda Pharmaceuticals, and Zafgen, Inc. L.J.A has
also performed contracted research for Amylin Pharmaceuticals, Inc., High Point Pharmaceuticals
LLC, Medical University of South Carolina (MUSC), and Novo Nordisk, and has ownership
interest in Cardiometabolic Support Network, LLC, and Myos Corporation.
D.M.R. has served as a clinical investigator in clinical drug trials of obesity therapeutics
for Orexigen; D.M.R. has not received any financial support as a consultant for Orexigen.
C.D.S. has participated on advisory boards for Allergan, and Ethicon-Endosurgery.
C.D.S. has also received research funding from Ethicon Endo-Surgery Arena and Orexigen
Pharmaceuticals.
H.W. received has served as an advisor for Orexigen Pharmaceuticals, Arena Pharmaceuticals,
Wellspring Camps, and Eisai, Inc. H.W. receives royalties from Up to Date and has
received grant funding from the NIH, Orexigen, and Novo Nordisk. H.W. has ownership
interests in Active Planet LLC and has co-ownership on a patent for a weight loss
maintenance strategy.
C.B. is an employee at Orexigen.
D.D.K. and E.D. are former employees at Orexigen; D.D.K. is currently employed at
Zafgen, Inc., and has acted as a consultant for Orexigen; E.D. is currently an employee
of Amgen, Inc.
Funding agencies: Orexigen Therapeutics, Inc., provided study drug and collaborated with the investigators
in the design of the study; interpretation of the data; and the preparation, review,
and approval of the manuscript. Metropolitan Research Associates (New York, New York,
USA) was responsible for study conduct and monitoring, and inVentiv Clinical Solutions
(Hunt Valley, Maryland, USA) was responsible for collection, management, and analysis
of the data. The dataset is available at Orexigen Therapeutics, Inc.